-

CEO, Jakob Lindberg, will attend the Nordic Life Science Days, 14-15 September 2016 in Stockholm Sweden.

Oncopeptides presented clinical results from a Phase 2 study of melflufen and dexamethasone in patients with relapsed-refractory multiple myeloma at the 21th European Hematology Association Congress in Copenhagen, Denmark, June 7 – 11.

The results can be downloaded below.

The results further support Oncopeptides’ belief that melflufen has the potential to make a meaningful difference in the lives of patients with relapsed-refractory multiple myeloma, providing a reliable go-to alternative even when conventional therapies have failed”.

For further information or to arrange a meeting for discussions please contact Jakob Lindberg (CEO) or Björn Hammarberg (BD).

Upcoming events

ASCO 2021 Annual Meeting

-

American Society of Clinical Oncology (ASCO) 2021.

EHA 2021 Virtual Congress

-

European Hematology Association Annual meeting 2021.

Silent Period

-

Interim Report Q2 2021

08:00 CET

Silent Period

-

Interim Report Q3 2021

08:00 CET